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Introduction
Most cancers acquire functional survival capabilities during their development. These capabilities include apoptosis evasion, self-sufficient growth signals, and insensitivity to antigrowth signals . Advanced-stage melanoma demonstrates these capabilities. For instance, a constitutively activate BRAF kinase is present in at least half of all advanced melanoma patients, driving melanoma proliferation . BRAF targeted therapy interrupts the growth signal and suppresses melanoma proliferation. Targeting BRAF mutation has led to outstanding clinical results with limited associated toxicity . However, the emergent resistance to BRAF inhibition limits the therapy's response duration, challenging our limited therapeutic options for advanced melanoma.
The modulation of nucleo-cytoplasmic protein transport has been suggested as a possible therapeutic strategy in the treatment of cancer . Protein transport between the nucleus and the cytoplasm is critical for cell maintenance, cell proliferation and survival. Alterations in the expression of nuclear-transport-related proteins, in particular Exportin 1 (XPO1, also known as Chromosome Region 1, CRM1) are found in melanoma and other cancers . Overexpression of CRM1 is linked to inactivation of tumor suppressor proteins, apoptosis evasion and resistance to chemotherapy . In addition, CRM1 expression is of prognostic value in several types of cancer . CRM1 mediates nuclear export using nuclear export signals (NES), which are required for nuclear cargo transport from the nucleus to the cytoplasm. Selective inhibitors of nuclear export (SINE) also known as KPT-analogs ( Figure 1 ; KPT-185, KPT-251, KPT-276 and KPT-330) are capable of binding to the Cys-528 residue in the cargo-binding portion of the CRM1 protein successfully preventing protein transport from the nucleus to the cytoplasm . The interruption of the system results in nuclear accumulation of the cargo, thereby restoring or disrupting cargo function. Among the CRM1 affected proteins, we find p42/44 MAPK (ERK1/2), CRM1 has been found to be overexpressed in metastatic melanoma when compared to nevi or even primary melanoma lesions. Moreover, CRM1 expression portrays independent of BRAF mutational status . This makes CRM1 a potential therapeutic target for metastatic melanoma.
Furthermore, the concurrent presence of CRM1-overexpression and increased BRAF activity offers the possibility of using simultaneous CRM1 and BRAF inhibition to reduce melanoma survival in BRAF mutant melanoma. Therefore, we hypothesize that the inhibition of CRM1 in melanoma will result in impaired melanoma viability. In addition, by inhibiting independent targets using a CRM1/BRAF combination in BRAF mutant melanoma, we will have enhanced anti-tumoral effects which could translate in improved clinical outcomes. 
Cell Proliferation Assays
Cellular proliferation was evaluated by MTT assay (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; Sigma-Aldrich) following manufacturer instructions. Cells were plated in 96-well plates at 1,000 to 10,000 cells per well in 100 μL of media 24 hours after treatment and MTT signal was read at 72 hours after treatment. The IC 50 and Combination Index (CI) by Chou-Talalay were determined from the regression plot logarithm of the concentration versus effect using Calcusyn Software (Biosoft) v1.1. In addition, conservative isobolograms were used to show synergism and/or antagonism. 
Cell cycle analysis by flow cytometry
Cell cycle analysis was carried out using Propidium iodide (PI) following manufacturer's protocol in package insert(BD pharmigen). 3x10 4 cells per analysis were examined by flow cytometry (FACS calibur), and analyzed using WinMDI 2.9.
Caspase 3/7 activity assay
Caspase 3/7 activity was determined using Promega #G8091 system, following manufacturer's protocol in package insert, and read using Victor3 multi-well reader (Wallac) and 1420 Wallac software.
Xenograft Model
Athymic nude mice Nu/Nu (Crl:NU-Foxn1nu), 4 weeks of age were purchased from Charles 
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We used caspase-3/7 activity as an apoptosis surrogate. Both CRM1 and BRAF inhibition increase caspase-3 and 7 activity in the tested melanoma cell lines in a dose and time related manner (p < 0.05) (Supplementary Figure 4) . A modest effect of BRAF inhibition on caspase activity in some of the BRAF mutant melanoma cell lines suggests cell cycle arrest over apoptosis as the predominant mechanism impacting cell proliferation in these cell lines, under the tested conditions. These findings correlate to the results from the cell cycle experiments.
The combination of both compounds results in a statistically significant increase in caspase activity when compared to either single therapy in BRAF mutant melanoma. This would correlate to strong synergy (CI < 0.3) for caspase-3/7 activity on BRAF mutant cell lines if the combination was taken as maximal effect and Chou-Talalay is applied. Despite slight increase in caspase activity after BRAF inhibition in BRAF WT cell lines after single drug treatment, the combination resulted in no statistically significant increase on caspase activity at tested doses when compared to CRM1 inhibition alone. For either single drug or combination studies, the effect on caspase activity was time-and dose-dependent and correlated to the sub-G1 changes observed in the cell cycle.
In melanoma xenograft models, CRM1 inhibition suppresses tumor growth, and induces complete regression of A375 Melanoma BRAF V600E tumors when combined with BRAF inhibition.
Oral administration of KPT-251 suppressed tumor growth in three xenograft models (Supplementary Figure. 5A ). Tumor growth suppression was associated with increased cleaved caspase-3 staining and a decreased Ki67 staining (Supplementary Figure 5B) . These findings suggest increased apoptosis, in addition to decreased cell proliferation. Similar to the in-vitro data, the effects of CRM1 inhibition were independent of BRAF and NRAS status. For our combination studies, BRAF inhibitor, PLX-4720 (preclinical PLX-4032 analog), was used due to better bioavailability. CRM1 inhibitors KPT-276 and KPT-330, structural analogs of KPT-251 with better bioavailability, were used to test BRAF and CRM1 combination in our BRAF V600E melanoma xenograft model. Both KPT-276 and PLX-4720 decreased tumor growth as single therapy. The combination of both inhibitors induced complete tumor regression per RECIST criteria ( Figure 4A , Red Line) and the difference between both single therapy and the combination therapy was statistically significant. These findings correlated to decreased cell proliferation and increased apoptosis when compared to the control group ( Figure 4B-C) . The effect on proliferation is not statistically different between treatment groups. We believe the greatest contribution of the combination is the effect on apoptosis, which is significantly increased (p < 0.05) by the drug combination. Decreased cell proliferation complemented by increased apoptosis explains the observed tumor regression. Treatment was stopped after 14 days, after which tumor growth was observed in all treatment groups. Survival for the combination group was statistically longer than for either single therapy. As single therapy and in combination, both inhibitors were well tolerated with no significant effect on animal weight. Similar results were observed using clinical grade analog KPT-330 in A2058, PTEN null / BRAF mutant melanoma cell line using a different treatment schedule (Supplementary Figure 6A-B) .
CRM1 inhibition modulates levels of p53, pRb, Survivin and ERK phosphorylation.
TP53 is a known tumor suppressor capable of inducing cell cycle arrest and apoptosis. functionally deficient for the tumor suppressor p53. The inhibition of nuclear export using the CRM1 inhibitor favors nuclear localization of p53 and prevents cytoplasmic p53 degradation ( Figure 5A-B) . The stabilization of p53 by CRM1 is independent of DNA damage ( Figure 5C ) and is associated with increased levels of p53 targets (i.e. p21 and HDM2) in p53 WT melanoma but not in p53 mutant cell lines . TP53 knockdown induced partial reduction of CRM1 effects on cell proliferation ( Figure 5D ) but not on caspase activity as single therapy or in the combination with BRAF inhibition (Supplementary Figure 7) . We can suggest that p53 has at least a partial role in the CRM1-mediated anti-tumoral effects. However, we must propose the existence of p53-independent mechanism(s) which contribute to the CRM1 p53-mediated effects . These alternative mechanisms would account for the remaining observed anti-tumoral activity and the resulting synergy of the combination. In addition, p53 nuclear localization is consistent after CRM1 inhibition and may serve as a marker of successful CRM1 inhibition.
Other proteins we found to be affected by CRM1 inhibition include tumor suppressor retinoblastoma protein, Survivin and ERK. Retinoblastoma protein (pRb) and its phosphorylation are both affected by CRM1 and BRAF inhibition. The combination of both agents further reduces pRb and p-pRb levels ( Figure 5E ). Hypo-phosphorylated pRb blocks proliferation by preventing the transcription of genes essential for cell cycle progression . These finding correlate to our cell cycle analysis suggesting a role for pRB in CRM1 mediated cell cycle arrest.
Both CRM1 and BRAF inhibition decrease Survivin levels. This finding is also seen after the drug combination ( Figure 5E ). Survivin, also called baculoviral inhibitor of apoptosis repeatcontaining 5 (BIRC5), is known as a bi functional protein for its role in cell division and apoptosis suppression. Survivin is constantly shuttling between the nucleus and the cytoplasm. 
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pool mediates its mitotic function. However, CRM1 inhibition disrupts the cell division and antiapoptotic functions of Survivin .
CRM1 inhibition increases ERK phosphorylation in both BRAF WT and Mutant ( Figure 5E ) (6) .
ERK phosphorylation after treatment with anti-tumoral agents has been described as a prosurvival event. Thus, phosphorylation of ERK following CRM1 inhibition could translate into enhanced chemo-resistance . Another tentative explanation would involve ERK nuclear localization as an anti-proliferative factor and further explaining CRM1-related anti-proliferative effects . Interestingly, the combination of the CRM1 inhibitor with the BRAF inhibitor prevents ERK phosphorylation ( Figure 5E ) and results in synergy between the two compounds. Our data suggest that the protection against CRM1-induced ERK phosphorylation by BRAF-inhibition may play a role in the synergistic response to combined therapy. Furthermore, our data supports that the inhibition of ERK phosphorylation may have a role in addressing ERKmediated chemo-resistance.
In conclusion, given the discovery of diverse mechanisms of acquired resistance to BRAF inhibitor therapy which are not readily countered with pharmacologic strategies, we believe a priority should be placed on developing BRAF inhibitor-based combinations to overcome de novo resistance and prevent the emergence of these acquired resistance mechanisms. We believe achieving this goal would translate into longer duration of response (Progression Free Survival) and will increase the percentage of treatment responders. Based on our data, CRM1/BRAF inhibitor combination can offer a benefit to the melanoma patient population. The combination of CRM1 and BRAF inhibition results in a synergistic decrease of cell proliferation, and increased apoptosis in BRAF mutant melanoma cell lines and xenograft models. We attribute the synergy of the combination to the inhibition of independent targets altering multiple essential factors of melanoma viability. In particular, we find that the abrogation of the CRM1- 
